Enteric coated risedronate 35mg for the treatment of osteoporosis

Description

In this Product Explainer, Endocrinologist Prof Ego Seeman explains the role of enteric coated risedronate 35mg for the treatment of osteoporosis (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Jeremy Grummet

A/Prof Jeremy Grummet

PSA Testing Demystified

Clinical A/Prof Lauren Sanders

Clinical A/Prof Lauren Sanders

Migraine Management Update

Dr Johanna Lynch

Dr Johanna Lynch

Trauma-Informed Care in GP

Prof Richard O'Brien

Prof Richard O'Brien

Prevention and Management of Diabetic Retinopathy

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Ego Seeman

expert

Prof Ego Seeman

Endocrinologist; Dept of Medicine and Endocrinology, Austin Health, University of Melbourne; Editor, Progress in Osteoporosis

Date published: 7 November 2023